Publications
Lin AM, Lin MP, Markovic D, Ovbiagele B, Sanossian N, Towfighi A. Less Than Ideal. Stroke. 2018. PMID: 30580724
Vijayaraghavan M, Dove MS, Stewart SL, Cummins SE, Schillinger D, Kohatsu ND, Tong EK. Racial/Ethnic Differences in the Response to Incentives for Quitline Engagement. American journal of preventive medicine. 2018. PMID: 30454673
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature medicine. 2018. PMID: 30291359
Kelley RK. Emerging Role for Systemic Therapy in Earlier Stages of HCC. International journal of radiation oncology, biology, physics. 2018. PMID: 31014785
Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. PMID: 30510087
Tong EK, Stewart SL, Schillinger D, Vijayaraghavan M, Dove MS, Epperson AE, Vela C, Kratochvil S, Anderson CM, Kirby CA, Zhu SH, Safier J, Sloss G, Kohatsu ND. The Medi-Cal Incentives to Quit Smoking Project: Impact of Statewide Outreach Through Health Channels. American journal of preventive medicine. 2018. PMID: 30454670
Wong EC, Kaplan CP, Dreher N, Hwang J, Van't Veer L, Melisko ME. Integration of Health Questionnaire Systems to Facilitate Supportive Care Services for Patients at an Academic Breast Care Center. JCO clinical cancer informatics. 2018. PMID: 30652601
Tempero M. An Oncologist's Letter to Santa: Bring Me Drugs! Journal of the National Comprehensive Cancer Network : JNCCN. 2018. PMID: 30545986
Koshkin VS, Basu A, Grivas P. Translational Cancer Research The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. 2018. PMID:
Rugo HS, Rifkin RM, Declerck P, Bair AH, Morgan G. Demystifying biosimilars: development, regulation and clinical use. Future oncology (London, England). 2018. PMID: 30500264
Spinner MA, Advani RH. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program. 2018. PMID: 30504311
Huimin Geng, Brice Tiret, Hua-Xin Gao, Cigall Kadoch, Ming Lu, Lingjing Chen, Ilwoo Park, Gerd Melkus, Adam Elkhaled, John Kurhanewicz, Lisa Drew, Sebastien Degorce, Michele Mayo, Keith Dillman, Rana Anjum, Andrew Bloecher, Myriam Chaumeil, James Rubenstein. Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. Blood. 2018. PMID:
Khoan Vu, James Rubenstein, Gabriel N. Mannis, Jimmy Hwang, Huimin Geng. Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma. Blood. 2018. PMID:
Li-Wen Huang, Chiung-Yu Huang, Charalambos Andreadis, Aaron C. Logan, Gabriel N. Mannis, Catherine C. Smith, Karin M. Gaensler, Thomas G. Martin, Lloyd E. Damon, Michael A. Steinman, Rebecca L. Olin. Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies. Blood. 2018. PMID:
Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Maria R. Baer, David F. Claxton, Joseph G. Jurcic, Ellen K. Ritchie, Stephen A. Strickland, Raoul Tibes, Jason E. Hill, Matt Rosales, Erkut Bahceci. Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leuke Blood. 2018. PMID:
Dennis J. Eastburn, Christine M. McMahon, Robert Durruthy-Durruthy, Martin Carroll, Catherine C. Smith, Alexander E. Perl. Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response. Blood. 2018. PMID:
Naval G. Daver, Daniel A Pollyea, Jacqueline S. Garcia, Brian A. Jonas, Karen W.L. Yee, Pierre Fenaux, Sarit Assouline, Norbert Vey, Rebecca Olin, Gail J. Roboz, Agostino Tafuri, Giuseppe Visani, Whitney Kirschbrown, Cherie Green, Connie Ma, Monique Dail, Jue Wang, Marion G Ott, Mehrdad Mobasher, Patrick Phuong, Wan-Jen Hong, Marina Y. Konopleva, Michael Andreeff. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. Blood. 2018. PMID:
Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. British journal of haematology. 2018. PMID: 30485408
Shi Y, Dincheva-Vogel L, Ayemoba CE, Fung JP, Bergamaschi C, Pavlakis GN, Farzaneh F, Gaensler KML. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice. Blood advances. 2018. PMID: 30482760
Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B, Dana-Farber Cancer Institute Inflammatory Breast Cancer Program. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clinical breast cancer. 2018. PMID: 30584057